title: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).
abstract: BACKGROUND
  Although paclitaxel was given triweekly in phase II trials prior to its approval for gastric cancer in Japan, it is currently more often delivered by a weekly schedule in the second-line setting.
  
  
  METHODS
  A phase II trial with response rate as the primary end-point was conducted. Patients with metastatic or unresectable gastric adenocarcinoma who had measurable lesions and had disease progression with the front-line chemotherapy were treated by weekly administration of paclitaxel at a dose of 80 mg/m2.
  
  
  RESULTS
  Forty-five patients were accrued and 44 were assessable for response. Partial responses were observed in 7 patients (16%). Stable disease was documented in further 14 patients (48%). Median progression-free survival of all patients enrolled was 2.6 months and median overall survival was 7.8 months. Toxicity was mild and manageable, the most frequent > or = grade 3 toxicity being neutropenia occurring in 16% of the patients.
  
  
  CONCLUSIONS
  With modest response rate, favorable toxicity profile, and progression-free or overall survival similar to those of more intense combination regimens, weekly paclitaxel remains a rational therapeutic option for gastric cancer refractory to the first-line chemotherapy.
authors: Department of Surgery II, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. ykodera@med.nagoya-u.ac.jp
authors: Yasuhiro
authors: Y
authors: Kodera
authors: Seiji
authors: S
authors: Ito
authors: Yoshinari
authors: Y
authors: Mochizuki
authors: Shinichi
authors: S
authors: Fujitake
authors: Katsumi
authors: K
authors: Koshikawa
authors: Yasuaki
authors: Y
authors: Kanyama
authors: Takanori
authors: T
authors: Matsui
authors: Hiroshi
authors: H
authors: Kojima
authors: Tsunenobu
authors: T
authors: Takase
authors: Norifumi
authors: N
authors: Ohashi
authors: Michitaka
authors: M
authors: Fujiwara
authors: Junichi
authors: J
authors: Sakamoto
authors: Nakao
authors: N
authors: Akimasa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel